A multimodal caffeic acid-derived alkyl-amide antidiabetic agent: targeting α-glucosidase, α-amylase, oxidative stress, and protein glycation.

ABSTRACT: Historically, natural products have been a primary source of new drugs and lead compounds. However, their direct application as therapeutic agents remains limited. Given the multifactorial nature of diabetes, therapeutic agents with multi-targeting properties offer a promising solution for effective management. Herein, we developed a library of seven lipophilic derivatives of caffeic acid (CA) and evaluated their multimodal antidiabetic activities. Among these, the most potent compound, CA14, showed an IC₅₀ of 1.94 μM, representing a 113-fold improvement over acarbose (IC₅₀ 219.70 μM). Further, compared to the parent compound CA (IC₅₀ 12 400 μM), CA14 was 6392 times more potent. Kinetic analysis revealed that CA14 acts as a competitive inhibitor of α-glucos

SUBMITTER: Kannan K 

PROVIDER: S-EPMC12573768 | biostudies-literature | 2025 Oct

REPOSITORIES: biostudies-literature